uBiome, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From uBiome, Inc.
Lilly Builds On Gene Therapy Focus With Akouos Takeout
With the planned $487m acquisition of sensorineural-focused Akouos, Lilly makes its second gene therapy M&A play in two years, on top of partnering/financing activity in the space.
Applied Therapeutics’ Pivotal Galactosemia Product Stalls, Confirming Analyst Concerns
Analysts’ fears have been confirmed as a US FDA demand for clinical outcomes data has forced Applied Therapeutics to delay a planned filing for its lead product candidate, AT-007, in the rare disease galactosemia based on biomarker data alone.
All Over For Servier's Autism Ambitions
The diuretic bumetanide had shown potential to improve the core symptoms of children and adolescents with autism in small studies but has failed to demonstrate any sign of effectiveness in two late-stage trials.
Tech Transfer Roundup: BridgeBio’s R&D Efforts Span New Seven New Agreements
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
Company Information
- Industry
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice